3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
106
Neoplasms
14
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Hereditary Sensory and Autonomic Neuropathies
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Malignancies
1
Recurrent Uterine Corpus Carcinoma
1
Neoplasms by Site
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Hormone Receptor Positive HER-2 Negative Breast Cancer
1
Hormone Receptor Positive Breast Cancer
1
HER2-positive Breast Cancer
1
Female Breast Carcinoma
1
Exanthema
1
Interventions
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
pembrolizumab
3
napabucasin
3
Paclitaxel
3
Irinotecan
3
selpercatinib
2
pralsetinib
2
patritumab
2
Standard of Care
2
Pemetrexed
2
Nivolumab
2
Fluorouracil
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Ascorbic Acid
2
Albumin-Bound Paclitaxel
2
valrubicin
1
sotorasib
1
ribociclib
1
relatlimab
1
pamiparib
1
osimertinib
1
ipatasertib
1
durvalumab
1
dostarlimab
1
cobimetinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms by Site
×
Fulvestrant
×
Clear all
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA